#ESMO26 🧬 KC-WISE | III 期
👥 246 例 | 赫赛汀治疗后 HER2+ 胃癌/胃食管结合部癌
💊 安贝尼单抗 + 化疗 vs 化疗
🚀 OS：19.6 对 9.6 个月 (HR 0.39; p<0.0001)
📈 PFS：7.1 对 2.7 个月 (IRC)
🎯 ORR：56% 对 14%
⚠️ G≥3 TEAEs：74.2% 对 54.5%
💡 显著生存获益，伴随毒性增加。
@OncoAlert
442 浏览 · 8 赞 · 8 转发 · 0 回复
Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgPatient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.org来源：Nieves Martinez Lago MD PhD · x.com